Related Party Transactions	6 Months Ended
Jun. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	13. Related Party Transactions As of June 30, 2022, Regeneron held 2,097,314 shares of common stock. During the three months ended June 30, 2022 and 2021, the Company recognized $2.2 million and $3.8 million as contra-research and development expense, respectively, in its condensed consolidated statements of operations and comprehensive (loss) income based on its progress towards completion of its research activities under the research plan for the Company’s collaboration with Regeneron. During the six months ended June 30, 2022 and 2021, the Company recognized $5.2 million and $5.7 million as contra-research and development expense, respectively, in its condensed consolidated statements of operations and comprehensive (loss) income based on its progress towards completion of its research activities under the research plan for the Company’s collaboration with Regeneron. As of June 30, 2022 and December 31, 2021, the Company had $10.0 million and $11.4 million, respectively, of unbilled accounts receivable due from Regeneron. As of June 30, 2022 and December 31, 2021, the Company did not have any amounts due to Regeneron. For the three months ended June 30, 2022 and 2021, the Company recorded no expenses and $0.1 million of expenses, respectively, relating to consulting services provided by an entity affiliated with a stockholder of the Company and a member of the Company’s board of directors. For the six months ended June 30, 2022 and 2021, the Company recorded no expenses and $0.2 million of expenses, respectively, relating to consulting services provided by an entity affiliated with a shareholder of the Company and a member of the Company’s board of directors. The Company terminated this arrangement effective December 31, 2021. As of June 30, 2022, the Company had no further amounts due to this entity. As of December 31, 2021, the Company had $0.1 million due to this entity, which was subsequently paid during the three months ended March 31, 2022.

Related Party Transactions

6 Months Ended

Jun. 30, 2022

13. Related Party Transactions

As of June 30, 2022, Regeneron held 2,097,314 shares of common stock. During the three months ended June 30, 2022 and 2021, the Company recognized $2.2 million and $3.8 million as contra-research and development expense, respectively, in its condensed consolidated statements of operations and comprehensive (loss) income based on its progress towards completion of its research activities under the research plan for the Company’s collaboration with Regeneron. During the six months ended June 30, 2022 and 2021, the Company recognized $5.2 million and $5.7 million as contra-research and development expense, respectively, in its condensed consolidated statements of operations and comprehensive (loss) income based on its progress towards completion of its research activities under the research plan for the Company’s collaboration with Regeneron. As of June 30, 2022 and December 31, 2021, the Company had $10.0 million and $11.4 million, respectively, of unbilled accounts receivable due from Regeneron. As of June 30, 2022 and December 31, 2021, the Company did not have any amounts due to Regeneron.

For the three months ended June 30, 2022 and 2021, the Company recorded no expenses and $0.1 million of expenses, respectively, relating to consulting services provided by an entity affiliated with a stockholder of the Company and a member of the Company’s board of directors. For the six months ended June 30, 2022 and 2021, the Company recorded no expenses and $0.2 million of expenses, respectively, relating to consulting services provided by an entity affiliated with a shareholder of the Company and a member of the Company’s board of directors. The Company terminated this arrangement effective December 31, 2021. As of June 30, 2022, the Company had no further amounts due to this entity. As of December 31, 2021, the Company had $0.1 million due to this entity, which was subsequently paid during the three months ended March 31, 2022.